I actually thought PDD/PD had a shot of making it to FDA approval ahead of AD after that report of the outstanding trial data in June of last year was released, since the PDD/PD trials are so much shorter and there was no doubt of approval.
Yes MIssling has deliberately slow walked this. Why?
I'd vote for the 500K of options upon P3 PD results.